Alexion Pharmaceuticals Inc. Release: New Data Presented At The ERA-EDTA Congress Demonstrate Efficacy Of Soliris® (Eculizumab) In Broad Range Of Patients With Atypical Hemolytic Uremic Syndrome (Ahus)

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers presented data from clinical trials supporting the chronic use of Soliris® (eculizumab) in a broad range of patients with atypical hemolytic uremic syndrome (aHUS), a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death.

Help employers find you! Check out all the jobs and post your resume.